

| TIME | LOCATION | PRESENTATION # | TITLE | LEAD AUTHOR | SESSION |
|------------------------------|---------------------|----------------|---|---------------------|--|
| SUNDAY, APRIL 2, 2017 | | | | | |
| 1:00 – 5:00 p.m. ET. | Section 26 | 617 | Evaluating the in-vitro effects of Tumor Treating Fields on T-cell responses | G. Diamant | PO.IM02.01 - T-cell Immunity to Cancer: New Progress |
| 1:00 – 5:00 p.m. ET. | Section 39 | 838 | Effect of Tumor Treating Fields on cell proliferation and synergistic antitumor efficacy in combination with ionizing radiation | E. Kim | PO.TB09.01 - Cellular Responses to Ionizing Radiation |
| 1:00 – 5:00 p.m. ET. | Section 42 | 900 | Tumor Treating Fields (TTFields) affect human glioma cell migration, invasion and adherence properties in vitro | D. Garcia-Carracedo | PO.TB10.01 - Migration and Invasion 1 |
| 3:00 – 5:00 p.m. ET. | Ballroom C, Level 3 | CT007 | Tumor Treating Fields added to standard chemotherapy in newly diagnosed glioblastoma (GBM). Final results of a randomized, multi-center phase III trial | R. Stupp | CTMS01 - Breast Cancer, Ovarian Cancer, and Glioblastoma Clinical Trials |

| MONDAY, APRIL 3, 2017 | | | | | |
|------------------------------|------------|-------|---|--------------|--|
| 8:00 a.m. – 12:00 p.m. ET. | Section 19 | 1504 | Tumor Treating Fields (TTFields) interfere with biological key properties of glioma cells in vitro | M. Silgner | PO.MCB08.02 - Mitochondria, Autophagy, and Cancer Metabolism |
| 8:00 a.m. – 12:00 p.m. ET. | Section 24 | 1569 | Optimizing transducer array configuration for treatment of pancreatic cancer using Tumor Treating Fields (TTFields) | A. Naveh | PO.BSB01.02 - Functional and Genomic Analysis of Cancer |
| 1:00 – 5:00 p.m. ET. | Section 33 | CT068 | Tumor Treating Fields in patients with glioblastomas: evaluation of treatment response using advanced MR imaging techniques | S. Chawla | PO.CT02 - Phase III Clinical Trials and Phase II/III Clinical Trials in Progress |
| 1:00 – 5:00 p.m. ET. | Section 33 | CT071 | LUNAR – A phase 3 trial of TTFields in combination with PD-1 inhibitors or docetaxel for second line treatment of non-small-cell lung cancer (NSCLC) | U. Weinberg | PO.CT02 - Phase III Clinical Trials and Phase II/III Clinical Trials in Progress |
| 1:00 – 5:00 p.m. ET. | Section 33 | CT160 | Modeling long term survival outcomes in glioblastoma patients treated with TTFields plus temozolomide and temozolomide monotherapy | G. Guzauskas | PO.CT02 - Phase III Clinical Trials and Phase II/III Clinical Trials in Progress |
| 1:00 – 5:00 p.m. ET. | Section 33 | CT051 | Tumor Treating Fields in pediatric recurrent high-grade glioma and ependymoma | S. Goldman | PO.CT02 - Phase III Clinical Trials and Phase II/III Clinical Trials in Progress |
| 1:00 – 5:00 p.m. ET. | Section 33 | CT161 | METIS: A phase 3 study of radiosurgery with TTFields for 1-10 brain metastases from NSCLC | M.P. Mehta | PO.CT02 - Phase III Clinical Trials and Phase II/III Clinical Trials in Progress |
| 1:00 – 5:00 p.m. ET. | Section 6 | 2138 | Tumor Treating Fields downregulate the BRCA1/FA pathway genes leading to reduced DNA repair capacity, the inhibition of mitophagy and enhanced cell death | N. Karanam | PO.ET01.09 - New Targets 2 |
| 1:00 – 5:00 p.m. ET. | Section 13 | 2312 | Feasibility study of a fractionation method in the treatment of Tumor Treating Fields | Y. Jo | PO.MCB02.01 - Apoptosis and Other Regulated Cell Death in Cancer |

| TUESDAY, APRIL 4, 2017 | | | | | |
|-------------------------------|------------|-------|--|------------------|--|
| 8:00 a.m. – 12:00 p.m. ET. | Section 33 | CT102 | Rates and impact of combination immunotherapy with Tumor Treating Fields in a glioma cohort | Y. Odia | PO.CT03 . Phase I Clinical Trials |
| 8:00 a.m. – 12:00 p.m. ET. | Section 13 | 3309 | Tumor Treating Fields decrease proliferation and clonogenicity of patient-derived WHO grade IV glioma cell lines | S.K. Michelhaugh | PO.MCB02.02. Autophagy and Cancer |
| 8:00 a.m. – 12:00 p.m. ET. | Section 13 | 3315 | Cancer cells upregulate autophagy as a survival mechanism in response to Tumor Treating Fields (TTFields) | Y. Porat | PO.MCB02.02. Autophagy and Cancer |
| 8:00 a.m. – 12:00 p.m. ET. | Section 27 | 3665 | Tumor Treating Fields (TTFields) plus anti-PD-1 therapy induce immunogenic cell death resulting in enhanced antitumor efficacy | T. Voloshin | PO.IM02.07 - Dendritic Cells as Critical Immune Targets |
| 8:00 a.m. – 12:00 p.m. ET. | Section 29 | 3730 | Early metabolic response to Tumor Treating Fields in patients with recurrent glioblastoma | S. Mittal | PO.CL01.04 - Clinical Laboratory and Imaging Correlates |
| 1:00 – 5:00 p.m. ET. | Section 33 | CT130 | PANOVA: A phase II study of TTFields (150 kHz) concomitant with standard chemotherapy for front-line therapy of advanced pancreatic adenocarcinoma | M. Benavides | PO.CT04. Phase I-III Clinical Trials and Pediatric Clinical Trials |
| 1:00 – 5:00 p.m. ET. | Section 33 | CT135 | INNOVATE: A phase II study of TTFields (200 kHz) concomitant with weekly paclitaxel for recurrent ovarian carcinoma | I. Vergote | PO.CT04. Phase I-III Clinical Trials and Pediatric Clinical Trials |
| 1:00 – 5:00 p.m. ET. | Section 33 | CT141 | Long term survival in glioblastoma patients after Tumor Treating Fields (TTFields) therapy | A.M. Rulseh | PO.CT04. Phase I-III Clinical Trials and Pediatric Clinical Trials |
| 1:00 – 5:00 p.m. ET. | Section 24 | 4536 | Using diffusion weighted imaging (DWI) data to accurately predict electric field delivery to the tumor during TTFields treatment | C. Wenger | PO.BSB01.05. Modeling and Algorithms |
| 1:00 – 5:00 p.m. ET. | Section 24 | 4528 | A novel transducer array design optimizing TTFields delivery to the thorax | H.S. Hershkovich | PO.BSB01.05. Modeling and Algorithms |

| WEDNESDAY, APRIL 5, 2017 | | | | | |
|---------------------------------|-----------|------|--|----------------|---|
| 8:00 a.m. – 12:00 p.m. ET. | Section 9 | 5228 | The impact of microtubules on solution conductance and capacitance; implications for the use of AC electric fields in cancer therapy | J.A. Tuszynski | PO.CH02.01 - Chemical Biology and Structure Biology Approach to Study Cancers |